Switching from one CD20-targeting therapy to another doesn't alter their ability to lower disease activity and slow ...

Zacks highlights research on Bank of America, Roche, Intuit, and microcap TSS, noting growth opportunities despite mixed industry trends.

This budget law is nothing but cruel. They threw billions at tax breaks for the wealthy without blinking, but keeping Arizonans with disabilities alive is too expensive.

As drug companies increasingly adopt the DTC sales model, patients will gain the ability to buy the medicines they need at ...

Halozyme Therapeutics reports a record Q2 2025, with 41% revenue growth. Discover raised guidance, strong catalysts, and shareholder-focused initiatives.

VANCOUVER, BC, Aug. 7, 2025 /CNW/ - Teresa Alfeld, a filmmaker who was recently diagnosed with multiple sclerosis (MS), is calling for the provincial ...

Eli Lilly is to buy the private biotech Disarm Therapeutics, which is working on a new class of disease-modifying drugs for neurological diseases, in a deal worth up to $1.36 billion.

Apitope aims to bounce back from MS setbackApitope hopes its MS hopeful ATX-MS-1467 will become a blockbuster, even though Merck KGaA walked away from clinical development at the end of last year ...

The experimental CAR T-cell therapy treatment was given as part of a clinical trial that's enrolling adults with progressive ...